Clinical trials: No Reflow
Myocardial Infarction, No Reflow Phenomenon
Validation of New Biomarkers for Predicting No-Reflow in STEMI Patients Undergoing Primary PCI
To evaluate the diagnostic value of the selected emerging biomarkers in predicting the no-reflow phenomenon among patients presenting with STEMI undergoing primary PCI.
- Trial name
- VaBiNoR (NCT07132489)
- Testing
- HbA1c/C-peptide ratio Albumin-bilirubin (ALBI) score. Neutrophil/HDL ratio
- Volunteers
- 114 people
- Sponsor
- Assiut University
Acute Myocardial Infarction (AMI)
Metabolic Profile as a Predictor of No-reflow in Diabetic Patients
to find metabolic factors that correlate with the development of no-reflow phenomenon that may help prevent its occurrence
- Trial name
- NCT04835207
- Testing
- 1- LDL-C (low-density lipoprotein cholesterol)| and HDL-C(high-density lipoprotein cholesterol) Ratio. 2- Glycemia will be assessed : RBS ( random blood sugar ) . 3- S
- Volunteers
- 120 people
- Sponsor
- El Zahraa Gamal
STEMI
Predictors of In-hospital and Short-term Clinical Outcomes in STEMI Patients Undergoing Primary PCI
The study aims to assess the culprit-SYNTAX score and no-reflow PIANO scores as possible predictors of in-hospital and short-term outcomes among patients with STEMI undergoing primary PCI
- Trial name
- NCT06123793
- Where
- Egypt
- Volunteers
- 500 people
- Sponsor
- Assiut University
No-Reflow Phenomenon
Mean Platelet Volume and STEMI Clinical Risk Scores in Prediction of Impaired Myocardial Perfusion In Acute STEMI Patients Undergoing Primary Percutaneous Coronary Intervention.
Predicting no reflow in ppci of STEMI patients using mean platelet volume together with STEMI clinical risk scores
- Trial name
- NCT04785209
- Testing
- Mean platelet volume, lymphocyte number, STEMI clinical risk scores
- Where
- Egypt
- Volunteers
- 640 people
- Sponsor
- Assiut University
Dipeptidyl-peptidase-4, STEMI
Plasma Dipeptidyl-peptidase-4 Activities With No-reflow and Bleeding
Dipeptidyl-peptidase-4 (DPP4) is an important regulator of incretins and inflammation, and participates in the pathophysiological process of acute myocardial infarction (AMI).
- Conditions
- Dipeptidyl-peptidase-4, STEMI, PCI, No-reflow
- Trial name
- NCT02849691
- Volunteers
- 747 people
- Sponsor
- Chinese PLA General Hospital
No-Reflow Phenomenon
the No-reflow in Diabetic Patients Treated With Primary Percutaneous Coronary Intervention (PCI)
1- to find metabolic factors that correlate with the development of no reflow phenomenon that may help prevent its occurrence .
- Trial name
- NCT04835974
- Testing
- 1- LDL-C (low-density lipoprotein cholesterol)| and HDL-C(high-density lipoprotein cholesterol) Ratio. 2- Glycemia will be assessed : RBS ( random blood sugar ) . 3- S
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Assiut University
Coronary Arteriosclerosis, Coronary Heart Disease
Analysis of Human Coronary Aspirate
During elective percutaneous coronary intervention (PCI), both proximal and distal protection devices are used. The distal occlusion protection device temporarily occludes the vessel distal to the lesion during the intervention…
- Conditions
- Coronary Arteriosclerosis, Coronary Heart Disease, No Reflow Phenomenon
- Trial name
- AHCA (NCT01430884)
- Testing
- Aspirated Coronary Blood
- Where
- Germany
- Volunteers
- 500 people
- Sponsor
- Universität Duisburg-Essen
Myocardial Infarction
Nitroprusside for Prevention of no-Reflow in Primary Angioplasty
In patients admitted with acute myocardial infarction, there is a total occlusion of a coronary artery. Even after emergency catheterization and angioplasty, in some patients, the resumed blood flow is suboptimal and impacts on…
- Trial name
- NCT00128791
- Testing
- Nitroprusside
- Where
- Israel
- Volunteers
- 100 people
- Sponsor
- Soroka University Medical Center